Screener
Summit Therapeutics SMMT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued compensation | 7,073 | 14,925 |
| Operating lease liabilities, current portion | 3,179 | 3,388 |
| Other current liabilities | 1,148 | 2,283 |
| Total current liabilities | 83,266 | 72,988 |
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 16,859 | 17,502 |
| Other non-current liabilities | 1,799 | 1,832 |
| Total liabilities | 101,924 | 92,322 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's total current liabilities?
- Summit Therapeutics (SMMT) reported total current liabilities of $83.27M in Q1 2026.
- How has Summit Therapeutics's total current liabilities changed year-over-year?
- Summit Therapeutics's total current liabilities increased by 138.7% year-over-year, from $34.88M to $83.27M.
- What is the long-term trend for Summit Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's total current liabilities has grown at a 29.7% compound annual growth rate (CAGR), from $19.89M to $72.99M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Summit Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude